Marksans Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)
Marksans Pharma Ltd · Outcome · 04 Nov 2026, 6:57 pm
Marksans Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 9,402 (+30.5% YoY | +11.8% QoQ) ■ EBITDA: 2,143 (+48.3% YoY | +0.6% QoQ) ■ EBITDA Margin (%): 22.8 (+274 bps YoY | -254 bps QoQ) ■ PAT: 1,413 (+43.8% YoY | -10.1% QoQ) ■ EPS (INR): 3.11 (+43.3% YoY | -10.4% QoQ)
Original exchange filing (PDF)
More announcements from Marksans Pharma Ltd
- Transcript of Investors/Analyst meet on Q2 FY27 Financial Results · 13 Nov 2026
- Audio Recording of investor(s)/analyst(s) meet Conference Call on Q2 FY 27 Financial Results · 05 Nov 2026
- Allotment of Equity Shares under Marksans Employees Stock Option Scheme 2024 · 04 Nov 2026
- Press Release for Financial Results Q2FY27 · 04 Nov 2026
- Investor Presentation Q2FY27 · 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30 September 2026 · 04 Nov 2026
- Marksans Pharma Limited has submitted to the Exchange, unaudited financial results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Intimation of schedule for Q2FY27 Earnings Conference Call · 05 Nov 2026
